Weighted Average Number of Shares Outstanding, Basic of Theriva Biologics, Inc. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Theriva Biologics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • Theriva Biologics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 12,140,697, a 801% increase year-over-year.
  • Theriva Biologics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 12,140,697, a 801% increase from 2024.
  • Theriva Biologics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 1,348,126, a 109% increase from 2023.
  • Theriva Biologics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 644,282, a 96% decline from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Theriva Biologics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 12,140,697 +10,792,571 +801% 01 Oct 2025 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 9,676,521 +8,542,130 +753% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 6,752,953 +5,977,217 +771% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 2,782,449 +2,096,526 +306% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 1,348,126 +703,844 +109% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2024 1,134,391 +452,683 +66% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 775,736 -14,390,473 -95% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 685,923 -14,438,138 -95% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 644,282 -14,683,046 -96% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 681,708 -15,162,353 -96% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 15,166,209 -677,852 -4.3% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 15,124,061 +1,303,917 +9.4% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 15,327,328 +3,139,824 +26% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 15,844,061 +2,639,807 +20% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 15,844,061 +2,639,807 +20% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 13,820,144 -76,987,549 -85% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 12,187,504 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 13,204,254 -6,194,085 -32% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 13,204,254 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 90,807,693 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 19,398,339 +2,593,082 +15% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q3 2019 16,805,257 +12,776,953 +317% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2019 2019 Q3
Q2 2019 16,465,314 +12,781,931 +347% 01 Apr 2019 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 15,656,784 +11,983,444 +326% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 13,442,104 +9,768,764 +266% 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2019 2018 FY
Q3 2018 4,028,304 +363,170 +9.9% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 3,683,383 +168,948 +4.8% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 3,673,340 +317,704 +9.5% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 3,673,340 -100,130,968 -96% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 3,665,134 -87,776,553 -96% 01 Jul 2017 30 Sep 2017 10-K 27 Feb 2019 2018 FY
Q2 2017 3,514,435 -87,501,298 -96% 01 Apr 2017 30 Jun 2017 10-K 27 Feb 2019 2018 FY
Q1 2017 3,355,636 -87,471,116 -96% 01 Jan 2017 31 Mar 2017 10-K 27 Feb 2019 2018 FY
Q4 2016 103,804,308 +12,993,679 +14% 01 Oct 2016 31 Dec 2016 10-K 22 Feb 2018 2017 FY
Q3 2016 91,441,687 +5,466,936 +6.4% 01 Jul 2016 30 Sep 2016 10-K 22 Feb 2018 2017 FY
Q2 2016 91,015,733 +18,278,904 +25% 01 Apr 2016 30 Jun 2016 10-K 22 Feb 2018 2017 FY
Q1 2016 90,826,752 +18,152,793 +25% 01 Jan 2016 31 Mar 2016 10-K 22 Feb 2018 2017 FY
Q4 2015 90,810,629 01 Oct 2015 31 Dec 2015 10-K 02 Mar 2017 2016 FY
Q3 2015 85,974,751 +27,521,223 +47% 01 Jul 2015 30 Sep 2015 10-K 02 Mar 2017 2016 FY
Q2 2015 72,736,829 01 Apr 2015 30 Jun 2015 10-K 02 Mar 2017 2016 FY
Q1 2015 72,673,959 01 Jan 2015 31 Mar 2015 10-K 02 Mar 2017 2016 FY
Q3 2014 58,453,528 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2011 27,885,479 +6,179,007 +28% 01 Apr 2011 30 Jun 2011 10-Q 15 Aug 2011 2011 Q2
Q2 2010 21,706,472 01 Apr 2010 30 Jun 2010 10-Q 15 Aug 2011 2011 Q2

Theriva Biologics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 12,140,697 +10,792,571 +801% 01 Jan 2025 31 Dec 2025 10-K 12 Mar 2026 2025 FY
2024 1,348,126 +703,844 +109% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2026 2025 FY
2023 644,282 -14,683,046 -96% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 15,327,328 +3,139,824 +26% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 12,187,504 -6,823,858 -36% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 19,011,362 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.